Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dermal dendritic cells (DDCs) are a **heterogeneous population of antigen-presenting leukocytes** resident in the dermis layer of the skin[7][8][5]. DDCs function as sentinels, capturing antigens from pathogens, processing them, and presenting them to T cells in the draining lymph node, thereby activating the adaptive immune response[7][9][5][8]. In addition to their role in host defense, these cells can induce peripheral tolerance or contribute to cutaneous inflammatory and autoimmune diseases. Functionally, DDCs exhibit traits of both dendritic cells and macrophages, with populations characterized by distinct markers such as CD1a (dendritic lineage) or CD209/CD206/CD163 (macrophage-like features)[7]. Importantly, "dermal dendritic cell" is an umbrella term that encompasses a mix of cell types and subpopulations (including CD103⁺, CD11b⁻, langerin⁺ DCs, and various macrophage-like cells), lacking a unique molecular identity. Several subtypes have distinct ontogeny, marker expression, and functional specialization, and some cells previously identified as DDCs have been reclassified as tissue macrophages[3][7]. There is no single protein, gene, or receptor uniquely defining the "dermal dendritic cell"; the term should be considered descriptive rather than as a molecular target for therapeutic purposes. Key notes: - The term **"dermal dendritic cell" is not a molecular target** (e.g., receptor, enzyme) but a heterogeneous cell population[7][8][3]. - The lack of unique, specific markers and the inclusion of both dendritic and macrophage-like cells mean this is not suitable for structured drug targeting as a single molecule[7][3]. - When referring to skin immune targets, specific surface proteins (e.g., Langerin, CD103, or CD11c) or well-defined DC subtypes should be used instead[2][3]. This entry is **not suitable** as a therapeutic target in the sense of receptor, enzyme, or other druggable entities, and should be flagged as incorrect or insufficient for structured target databases[7][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dermal dendritic cell (DDC).